Clinical Trial Update: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. [Phase 1]

View source ↗

Summary

Phase I/II study evaluating continuous oral BIBF 1120 (nintedanib) added to standard gemcitabine/cisplatin therapy in first-line non-small cell lung cancer with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIBF 1120 (nintedanib) (nintedanib)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2018-09-10